What is the immunological response to BNT162b2 mRNA vaccine in immunocompromised patients?
Saved in:
Main Author: | Nicola Silvestris |
---|---|
Format: | article |
Language: | EN |
Published: |
Elsevier
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/9818b25054714dda8dc3970dda1d96f3 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety and humoral responses to BNT162b2 mRNA vaccination of SARS-CoV-2 previously infected and naive populations
by: Shai Efrati, et al.
Published: (2021) -
Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination
by: Yamato Nishiguchi, et al.
Published: (2021) -
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial
by: Peter Bergman, MD, et al.
Published: (2021) -
Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report
by: Serge Goldman, et al.
Published: (2021) -
Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell's palsy: a population-based study
by: Rana Shibli, et al.
Published: (2021)